AbbVie's (ABBV) HUMIRA Receives FDA Approval as Non-Infectious Intermediate, Posterior and Panuveitis Treatment
Tweet Send to a Friend
AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA® (adalimumab) for the treatment of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
